BioRestorative Therapies (BRTX) - יחס רווח גולמי

BioRestorative Therapies brings together leading scientists to develop spinal treatments. The change in gross margin confirms this trajectory, where the current parameter is 33.20. BioRestorative Therapies owns the unique ThermoStem platform for metabolism therapy; however, the lack of sales and trial costs create a severe liquidity deficit and a cash gap.
פילוחי מדדים מקיפים ואנליטיקה עבור biorestorative.com (BRTX)

The cell therapy development of BioRestorative Therapies (BRTX) possesses high macro-resilience, as clinical progress remains independent of economic cycles. This metric measures the share of revenue minus direct production costs, reflecting the efficiency of the operating model and the capital intensity of the asset. By analyzing the gross profit margin, an investor can assess the real business return and identify risks of value depreciation in a timely manner.